Today: 19 May 2026
Browse Category

SWX:NOVN.SW 26 November 2025 - 7 December 2025

MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

The MSCI Europe Index closed at 2,564.76 on Dec. 5, down 0.25% after a recent rally, but remains up about 12.5% to 15.5% year-to-date in 2025. The index outpaces the MSCI World, which is up roughly 7.7% for the year. European stocks continue to trade at lower valuations, with a 3.03% dividend yield and forward P/E of 14.64. The MSCI Europe Index has 402 constituents and a market cap near $12.85 trillion.
7 December 2025
···········
Swiss Stock Market Today, 26 November 2025: SMI Edges Higher as Sentiment Surges and Insurers Face Tougher Rules

Swiss Stock Market Today, 26 November 2025: SMI Edges Higher as Sentiment Surges and Insurers Face Tougher Rules

The Swiss Market Index closed up 0.07% at 12,781.09 on Wednesday, its highest in about a week, extending a three-day advance. Turnover topped 2.4 million contracts. Investor sentiment jumped after a thaw in Swiss-US trade tensions. Zurich Insurance, Swiss Re, and Swiss Life drew attention after being added to the G20 Financial Stability Board’s insurer resolution list.
26 November 2025
········

Stock Market Today

  • Rocket Lab (RKLB) Soars Near $125 As Retail Investors Eye SpaceX Alternative
    May 19, 2026, 5:10 AM EDT. Rocket Lab (RKLB) stock surged to nearly $125 in May 2026, up from a 52-week low of $23.92, driven by strong Q1 results and renewed investor interest. Q1 2026 revenue jumped 63.5% year-over-year to $200.3 million, with Space Systems segment leading at $136.7 million. The company's Electron rocket achieved a 100% success rate in 2025, while the upcoming Neutron medium-lift reusable rocket targets a $50 million price point, aiming to compete with SpaceX's Falcon 9. Rocket Lab boasts a $2.2 billion backlog and improved gross margins at 38.2% GAAP. Despite expanding cash reserves of $1.48 billion, RKLB trades at a high valuation of 90 times annualized sales, reflecting market optimism tempered by risks including cash burn, competition, and launch execution.

Latest articles

NextEra shares dip after $66.8B Dominion deal—What’s on traders’ radar now

NextEra shares dip after $66.8B Dominion deal—What’s on traders’ radar now

19 May 2026
NextEra Energy shares fell 4.6% to $89.04 late Monday after announcing a $66.8 billion stock-led merger with Dominion Energy, whose shares rose 9.4% to $67.56. The deal would create one of the world’s largest electric utilities, serving about 10 million customer accounts and owning 110 gigawatts of generation across four states.
Costco Stock Just Hit a High—Here’s the Next Thing Traders Are Watching

Costco Stock Just Hit a High—Here’s the Next Thing Traders Are Watching

19 May 2026
Costco shares closed Monday up 2.62% at $1,076.47, marking a fifth straight gain and outpacing Walmart and Target. April net sales rose 13% to $23.92 billion, with comparable sales up 11.6%. The company will report fiscal third-quarter earnings on May 28. Analysts’ average price target is $1,072.91, just below Monday’s close.
T1 Energy Stock Just Popped 23%. The Filing Behind the Move Is the Story

T1 Energy Stock Just Popped 23%. The Filing Behind the Move Is the Story

19 May 2026
T1 Energy Inc. shares surged 23.46% to $7.00 Monday after a regulatory filing revealed Situational Awareness LP held 10 million shares, valued at $43.9 million as of March 31. Trading volume hit 88 million shares, far above the 20-day average. T1 reported Q1 net sales of $177.6 million and a net loss to common stockholders of $21.4 million. Construction at its G2_Austin solar site remains on schedule.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Go toTop